Creation and characterization of mice with selective mutation of the cyclic GMP-dependent protein kinase I interaction domain by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open AccessOral presentation
Creation and characterization of mice with selective mutation of 
the cyclic GMP-dependent protein kinase I interaction domain
Michael E Mendelsohn*
Address: Molecular Cardiology Research Institute, Tufts-New England Medical Center, Tufts-University School of Medicine, Boston, MA, 02111, 
USA
Email: Michael E Mendelsohn* - MMendelsohn@tufts-nemc.org
* Corresponding author    
Vascular tone is dynamically regulated by vascular
smooth muscle cell contractile state. Vascular contraction
by many agonists is mediated by Gq-coupled receptor acti-
vation, calcium mobilization and myosin light chain
(MLC) phosphorylation. Nitric oxide (NO) inhibits vas-
cular contraction by activating cGMP-dependent protein
kinase I α (PKGI-α), which causes MLC dephosphoryla-
tion and vascular smooth muscle relaxation. Cyclic GMP-
dependent protein kinase I (PKGI) is the principle effector
of nitric oxide (NO) signaling in vascular smooth muscle
cells (VSMC). Activation of PKGI? by NO signaling has
several effects in VSMC, including activation of myosin
phosphatase (PP1M), which dephosphorylates the
myosin light chain, causing relaxation. We have shown
that PKGIα binds directly to the MBS subunit of the PP1M
phosphatase via leucine zipper (LZ) motifs in each pro-
tein, providing a molecular basis for the effects of NO and
cGMP on vascular relaxation. In recent studies, we found
that PKGI-α also attenuates signaling by the Gq-coupled
thrombin receptor PAR-1 by directly activating the regula-
tor of G-protein signaling, RGS2. The same PKGI-α LZ
domain that interacts with PP1M also mediates binding of
PKGIα to RGS2. PKGI phosphorylates RGS2 and thereby
activates the GTPase activity of Gq, inhibiting PAR-1 sign-
aling. In addition, Rgs2-/- mouse blood vessels have
enhanced contraction and decreased cGMP-mediated
relaxation, and these mice have marked hypertension. The
presence of vasomotor dysfunction and hypertension in
the RGS-2 knockout mice raises the possibility that intrin-
sic abnormalities of VSMC relaxation alone are sufficient
to cause hypertension. To explore this hypothesis and the
role pf PKGIα in regulation of vascular tone and blood
pressure, we have used gene targeting to generate mice
that express a LZ mutant (LZM) form of PKGIα in which
critical amino acids in the leucine zipper motif have been
substituted to disrupt LZ binding. The generation and
characterization of the LZM mice will be described and
data from LZM mouse studies will be presented. The stud-
ies support an essential role for PKGIα in maintenance of
normal vascular tone and blood pressure and are consist-
ent with the hypothesis that intrinsic abnormalities of
VSMC regulation can be a primary, non-renal cause of
high blood pressure.
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